| Adalimumab n = 267 | Etanercept n = 289 | Infliximab n = 151 | p Value | Missing values (%) | |
| Rheumatoid factor + (%) | 81.0 | 71.1 | 77.7 | 0.022 | 1 |
| Female (%) | 70.0 | 68.9 | 70.2 | 0.939 | 0 |
| With ⩾ one erosion (%) | 71.7 | 65.3 | 72.7 | 0.157 | 1 |
| Age | 55.1 (12.6) | 54.6 (14.2) | 57.8 (13.4) | 0.05 | 0 |
| Disease duration (years)* | 7.7 (2.7–13.6) | 6 (2.1–13.4) | 7.7 (2.7–14.1) | 0.356 | 1 |
| N previous DMARDs* | 3 (2–4) | 3 (2–4.75) | 3 (2–5) | 0.385 | 0 |
| HAQ | 1.3 (0.7) | 1.4 (0.7) | 1.4(0.7) | 0.176 | 10 |
| DAS28 | 5.3 (1.3) | 5.5 (1.2) | 5.2 (1.3) | 0.059 | 4 |
Values are presented as means (SD) unless stated otherwise.
*Median (interquartile range).
DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire.